CHICAGO, Feb. 28, 2011 /PRNewswire/ -- Zacks.com Analyst Blog features: Salesforce.com Inc. (NYSE: CRM), WellPoint Inc. (NYSE: WLP), Cigna Corp. (NYSE: CI), Unitedhealth Group (NYSE: UNH) and Express Scripts (Nasdaq: ESRX).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579
Here are highlights from Friday's Analyst Blog:
Salesforce.com Posts Decent 4Q
Salesforce.com Inc. (NYSE: CRM) reported fourth quarter fiscal 2011 adjusted net income of 12 cents per share, at par with the Zacks Consensus Estimate. The adjusted figure excludes amortization of intangibles and debt discount, but includes stock-based compensation.
Revenues
Revenues in the quarter were $456.9 million, up 29.0% from $354.0 million in the year-ago quarter. Results exceeded the company's guidance range of $447.0 million to $449.0 million and the Zacks Consensus Estimate of $453.0 million. The company witnessed robust demand for its products, along with broad-based revenue strength across all geographical regions.
Going by segments, Subscription and Support revenues of $428.5 million escalated 30.9% from the year-ago quarter. Professional Services and Other revenues increased 6.0% from the year-earlier quarter to $28.3 million.
Geographically, on a year-over-year basis, the Americas improved 26.2% to generate $308.5 million, contributing 67.5% to the total revenue, Europe grew 29.5% to $82.9 million, contributing 18.1% and Asia-Pacific leaped 43.1% to $65.4 million, contributing 14.3%.
New customers increased sequentially by approximately 5,100 during the quarter. The number of net paying customers at the end of the first quarter was 92,300. During fiscal 2011, Salesforce.com added 19,800 net paying customers, compared to 19,300 in the prior quarter.
WellPoint Provides 2011 Guidance
WellPoint Inc. (NYSE: WLP), at its investor conference provided its guidance for full year 2011. The company reaffirmed its expectation of delivering net income of least $6.30 per share. The Zacks Consensus Estimates for 2011 is in line with the company's guidance. The company also expects to achieve earnings per share growth of at least 10% over a longer term.
WellPoint expects operating revenue to be $59.5 million in 2011, up 3% year over year. The company also expects Medical enrollment growth in the National, State Sponsored, Senior and Federal Employee Plan businesses, partially offset by attrition in Local Group and Individual.
Selling, General and Administrative (SG&A) expenses are likely to decrease $400 million or 4.5%, and the SG&A Expense Ratio is projected to be 14.2%, a decrease of 110 basis points over the prior year. WellPoint estimates the benefit expense ratio to likely increase by 170 basis points to 84.9% in 2011
WellPoint expects to generate cash flow from operations of $2.6 billion in 2011.
Additionally, the board of directors of WellPoint Inc. approved an increase in share buyback authorization to $1.6 billion for 2011. The company will utilize this authorization by 2011 end. During 2010, the company bought back 76.7 million shares of its stock for approximately $4.4 billion.
The board of directors also declared first quarter 2011 dividend of 25 cents per share, representing an annualized dividend of $1.00per share. The dividend will be paid to shareholders of record as of March 10, 2011on March 25, 2011.
The dividend represents an yield of 1.5%, higher than that of industry average of 1.11%. The company's dividend yield also exceeds that of its nearest peers, Cigna Corp.'s (NYSE: CI) yield of 0.09% and Unitedhealth Group's (NYSE: UNH) yield of 1.17%.
WellPoint Inc. reported its fourth-quarter income from continuing operations of $1.33 per share, surpassing the Zacks Consensus Estimate of $1.21and $1.16 in the year-ago quarter. Fiscal 2010 earnings were $6.74 per share, surpassing the Zacks Consensus Estimate of $6.60 and $6.09 earned in 2009.
The improvement was attributable to higher operating cash flows and the implementation of organizational changes in the health care. The sale of NextRx pharmacy benefit management subsidiaries to Express Scripts (Nasdaq: ESRX) in the fourth quarter of 2009 also contributed a significant return of capital.
The Zacks Consensus Estimate for first-quarter 2011 is $1.89 per share. For full year 2012, the Zacks Consensus Estimates is $7.31 per share.
We maintain our long-term Neutral recommendation on WellPoint. The quantitative Zacks #3 Rank (short-term Hold rating) for the company indicates no clear directional pressure on the stock over the near term.
Based in Indianapolis, Indiana and formed in November 2004 through the merger of Anthem Inc. and WellPoint Health Networks Inc., WellPoint Inc. is the largest publicly traded managed care organization in terms of membership.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5514.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5516
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/ZacksResearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: |
|
Mark Vickery |
|
Web Content Editor |
|
312-265-9380 |
|
Visit: www.zacks.com |
|
SOURCE Zacks Investment Research, Inc.
Share this article